Aduro Biotech Announces Milestone Achieved under Merck Collaboration for Initiation of Phase 2 Trial of Anti-CD27 Agonist MK-5890 in Non-Small Cell Lung Cancer

https://investors.aduro.com/news-releases/news-release-details/aduro-biotech-announces-milestone-achieved-under-merck
JOIN OUR MAILING LIST